10-K: Catalyst Pharma Soars on AGAMREE Launch, FIRDAPSE Growth

Catalyst Pharmaceuticals reported significant revenue and net income growth in its 2025 annual report, primarily fueled by the successful commercialization of AGAMREE and continued FIRDAPSE sales, despite generic competition for FYCOMPA.

Summary

• Total revenues for fiscal year 2025 reached approximately $589.0 million, an increase from $491.7 million in 2024.
• Net product revenue for FIRDAPSE increased by 17.1% to $358.4 million in 2025 from $306.0 million in 2024.
• AGAMREE, launched in March 2024, generated approximately $117.1 million in net product revenue in 2025, up from $46.0 million in the partial year of 2024.
• FYCOMPA net product revenue decreased by 17.4% to $113.3 million in 2025 from $137.3 million in 2024, due to generic competition following patent expiration.
• Net income for 2025 was approximately $214.3 million ($1.75 per basic share), compared to $163.9 million ($1.38 per basic share) in 2024.
• Cash and cash equivalents stood at approximately $709.2 million as of December 31, 2025, up from $517.6 million at December 31, 2024.
• A new share repurchase program was authorized on October 1, 2025, for up to $200 million, with $39.9 million repurchased as of February 23, 2026.
• FIRDAPSE patent litigation against Hetero USA, Inc. is ongoing, with a trial scheduled for March 23, 2026.
• AGAMREE received regulatory approvals in Canada (October 2, 2025), Germany (January 15, 2024), UK (January 12, 2024), and Switzerland (January 15, 2026).
• FIRDAPSE royalty rates to immediate licensor decreased from 7-10% to 0% on January 25, 2026, and to third-party licensor from 7% to 3.5% on November 28, 2025, resulting in an overall royalty rate of 6% for net U.S. sales of FIRDAPSE from January 26, 2026.

Sentiment

Score: 8

Explanation: StockSavvy.ai views this as a strong report, driven by significant revenue and net income growth from successful product commercialization and strategic initiatives, despite the expected decline in FYCOMPA sales due to generic competition and ongoing litigation risks.

Positives

• Significant increase in total revenues to $589.0 million in 2025, up from $491.7 million in 2024.
• Strong growth in FIRDAPSE net product revenue, increasing 17.1% to $358.4 million in 2025.
• Successful commercial launch and rapid revenue ramp-up for AGAMREE, generating $117.1 million in 2025.
• Net income increased substantially to $214.3 million in 2025 from $163.9 million in 2024.
• Robust cash and cash equivalents position of $709.2 million at year-end 2025, providing strong liquidity.
• Authorization of a new $200 million share repurchase program, demonstrating confidence in financial health and commitment to shareholder returns.
• Favorable settlements in FIRDAPSE patent litigation with Inventia, Teva, and Lupin, securing market exclusivity until at least February 25, 2035, for Teva and Lupin.
• Inclusion of LEMS and amifampridine in the NCCN Clinical Practice Guidelines for Small Cell Lung Cancer, potentially increasing FIRDAPSE patient identification and treatment.
• AGAMREE received multiple international regulatory approvals (Canada, UK, Germany, Switzerland), expanding its market reach.
• Reduced overall royalty rate for FIRDAPSE U.S. net sales to 6% starting January 26, 2026, down from a previous maximum of 18.5%.
• Strategic investment in Santhera Pharmaceuticals Holding AG, acquiring an 11.26% stake, which has appreciated in value (CHF 9.477 to CHF 16.46 per share).

Negatives

• FYCOMPA net product revenue decreased by 17.4% to $113.3 million in 2025 due to generic competition, and further declines are expected.
• Ongoing FIRDAPSE patent litigation against Hetero USA, Inc. creates uncertainty regarding future generic competition for FIRDAPSE.
• The compassionate use program for RUZURGI has been discontinued due to the unavailability of its API, impacting patients with neuromuscular conditions other than LEMS.
• Increased selling, general, and administrative expenses by 9.0% to $193.8 million in 2025, driven by compensation and business development activities.
• The increase in accounts receivable by $61.0 million in 2025 was primarily due to a change in customer payment terms, delaying a $27.0 million payment into January 2026.

Risks

• Success depends on the successful commercialization of FIRDAPSE and AGAMREE, and continued sales of FYCOMPA amidst generic competition.
• Drug products may fail to receive the degree of market acceptance by physicians, patients, and third-party payers necessary for commercial success.
• The business is subject to substantial competition from other pharmaceutical and biotechnology companies, including generic competition.
• Potential adverse effects from tariffs on pharmaceutical imports, increasing costs or delaying product manufacture.
• Uncertainty regarding government and health insurer reimbursement and pricing policies, including Most Favored Nation (MFN) pricing and the Inflation Reduction Act (IRA).
• Strategy to acquire or in-license additional drug development programs may not be successful, or acquisitions may entail operational, financial, and legal risks.
• Small target patient populations for FIRDAPSE and AGAMREE necessitate significant market share and high per-patient prices for meaningful gross margins, which may not be sustainable.
• Risks associated with FYCOMPA's boxed warning for serious psychiatric and behavioral changes, potentially leading to patient reluctance or discontinuation.
• Drug development efforts can fail at any stage, leading to delays or inability to obtain regulatory approval for additional indications.
• Reliance on third parties to conduct pre-clinical and clinical studies and trials, and for manufacturing and supply, poses risks of delays, non-compliance, or supply shortages.
• Commercialization and collaborative arrangements may lead to disputes over terms, intellectual property, or partner performance.
• Difficulties in managing growth, including hiring, training, and managing additional employees and expanding product development activities.
• Internal computer systems or those of third-party vendors are vulnerable to cyber-attacks and security breaches, potentially disrupting business or compromising data.
• Risk of fraud or misconduct by employees, sales agents, or consultants, including non-compliance with regulatory standards and healthcare fraud and abuse laws.
• The healthcare industry is highly regulated, and unexpected changes in interpretation or enforcement could adversely impact the business.
• Lengthy regulatory approval processes and potential delays from FDA disruptions (e.g., government shutdowns).
• Inability to recruit or retain patients for clinical studies, especially for rare diseases.
• Failure to obtain or maintain orphan drug exclusivity or regulatory exclusivity for FIRDAPSE, AGAMREE, and future candidates, leading to generic competition.
• Changes to the Orphan Drug Act or successful legal challenges to FDA's interpretation of it could affect exclusivity.
• Litigation costs and diversion of management resources due to patent and intellectual property disputes.
• Dependence on a small number of key personnel and advisors.
• Risk of product liability claims from clinical testing, manufacture, or sale of products.
• Unfavorable global economic conditions, health epidemics, military conflicts, or geopolitical disputes could adversely affect business and financial results.
• Increasing focus by investors, regulators, customers, and stakeholders on environmental, social & governance (ESG) disclosures and potential reputational or financial impacts if standards are not met.
• Volatility in the trading price of common stock.
• Delaware law and company certificate of incorporation and by-laws contain provisions that could delay and discourage takeover attempts that stockholders may consider favorable.
• Future sales of common stock may cause the stock price to decline.

Future Outlook

The company plans to continue commercializing FIRDAPSE and AGAMREE, seeking to develop additional indications for both products, and actively pursuing the acquisition or in-licensing of new rare disease drug products. It expects FYCOMPA net product revenue to continue decreasing due to generic competition. The company anticipates completing the transition of AGAMREE manufacturing to a U.S. location by the end of 2026 and expects results from a Phase 1 study comparing AGAMREE to other corticosteroids by the end of Q2 2026. The ongoing FIRDAPSE patent litigation with Hetero is scheduled for trial in March 2026, with an uncertain outcome.

Management Comments

• "We believe that this most recent sNDA approval offers healthcare providers and patients greater flexibility in treatment regimens for the management of LEMS."
• "We are currently working to get these guidelines [NCCN Clinical Practice Guidelines for SCLC] into the standard of care followed by oncology practices that treat patients with SCLC."
• "We believe that by using specialty pharmacies in this way, the task, which can be difficult, of navigating the health care system is far better for the patient needing treatment for their rare disease and the health care community in general."
• "Subject to compliance with applicable regulatory requirements, our goal is that no LEMS patient is ever denied access to their medication for financial reasons."
• "We believe that steroids are and will continue to remain the foundational therapy for DMD patients and dosed concomitantly with other therapies."
• "AGAMREEs unique mode of action is based on differential effects on glucocorticoid and mineralocorticoid receptors and modifying further downstream activity. As such, it is considered a novel corticosteroid that we hope has the potential to demonstrate comparable efficacy to corticosteroids, with the potential for a better-tolerated side effect profile."
• "Our goal is to ensure that no DMD patient is ever denied access to their medication for financial reasons."
• "We believe that we have sufficient funds to support our operations for at least the next 12 months."
• "We also believe that we can execute this share repurchase program without impairing the advancement of our business development strategy."
• "Our goal is to acquire and integrate high-value, orphan designated, synergistic assets. We are dedicated to making a meaningful impact on the lives of those suffering from rare diseases, and we believe in putting patients first in everything we do."

Industry Context

StockSavvy.ai notes that Catalyst Pharmaceuticals' strong performance in 2025, particularly with AGAMREE's launch and FIRDAPSE's continued growth, positions it well within the competitive rare disease biopharmaceutical market. The company's strategic focus on in-licensing and developing orphan drugs aligns with a broader industry trend of targeting high-unmet-need conditions, which often command premium pricing and benefit from extended exclusivities. The decline in FYCOMPA revenue due to generic entry highlights the inherent challenge of patent cliffs in the pharmaceutical sector, underscoring the importance of a diversified portfolio and continuous pipeline development. The increasing regulatory scrutiny on drug pricing, including potential MFN policies and the IRA, represents a significant headwind for the entire industry, particularly for companies relying on high-cost orphan drugs. The company's efforts to expand FIRDAPSE and AGAMREE indications and global reach are crucial for long-term sustainability in this dynamic environment.

Comparison to Industry Standards

• AGAMREE is positioned as a novel corticosteroid for DMD, hoping to demonstrate comparable efficacy to existing corticosteroids with a better-tolerated side effect profile, potentially offering an advantage over standard treatments like Emflaza (deflazacort) by PTC Therapeutics.
• The DMD treatment market is highly competitive, with gene therapy treatments like Elevidys by Sarepta Therapeutics also approved. Elevidys initially had a restricted label but received an expanded label in June 2024, then a restriction in July 2025 to only ambulatory patients, indicating a dynamic competitive landscape.
• The company believes that corticosteroids like AGAMREE will remain foundational therapy for DMD, even with the emergence of gene therapies, suggesting a strategy of co-treatment or sequential treatment rather than direct replacement.
• FIRDAPSE competes with unapproved drugs and therapies for LEMS, including steroids, azathioprine, and pyridostigmine, as well as older approved drug guanidine HCl tablets, which has significant side effects. The inclusion of FIRDAPSE in NCCN guidelines for SCLC-related LEMS is a significant step towards establishing it as a standard of care, differentiating it from other treatments.
• FYCOMPA, as the first and only AED targeting AMPA receptors, offers a novel mechanism of action compared to traditional AEDs like benzodiazepines, GABA inhibitors, and sodium channel blockers, but faces direct generic competition.

Legal Proceedings

• Ongoing Paragraph IV patent litigation against Hetero USA, Inc. regarding FIRDAPSE patents expiring in 2032, 2034, and 2037. Trial is scheduled to start on March 23, 2026.
• Settled FIRDAPSE patent litigation with Inventia Healthcare Limited on July 30, 2024, where Inventia acknowledged patent validity and infringement, agreeing not to commercialize until earlier of patent expiration (2037) or entry of another ANDA product.
• Settled FIRDAPSE patent litigation with Teva Pharmaceuticals USA, Inc. on January 8, 2025, with Teva agreeing not to market a generic version before February 25, 2035.
• Settled FIRDAPSE patent litigation with Lupin Pharmaceuticals, Inc. on August 26, 2025, on substantially the same terms as Teva. Lupin had previously converted five Paragraph IV certifications to Paragraph III in June 2024, acknowledging validity and infringement for patents expiring latest in 2034, but maintained a Paragraph IV for a patent expiring in 2037.
• Settled FYCOMPA Paragraph IV patent litigation in June 2024, with the filer agreeing not to commercialize proposed ANDA products for oral suspension and tablets until at least December 15, 2025.

Stakeholder Impact

• Shareholders: Potential for increased value through share repurchase program and continued revenue growth from FIRDAPSE and AGAMREE. Risk of stock price volatility due to litigation outcomes, generic competition, and broader market factors. Dilution risk from future equity offerings.
• Patients (LEMS): Continued access to FIRDAPSE, with increased maximum daily dosage flexibility. Enhanced awareness and diagnosis through NCCN guidelines. Financial assistance programs aim to ensure no patient is denied access for financial reasons.
• Patients (DMD): Access to AGAMREE, a novel corticosteroid with potential for better-tolerated side effects. Patient support programs (Catalyst Pathways) and financial assistance. Potential for new indications and long-term safety data from SUMMIT registry.
• Patients (Epilepsy): Continued access to FYCOMPA, but active marketing efforts ceased due to generic competition, potentially impacting awareness and new patient acquisition.
• Employees: Growth in headcount, particularly in commercial teams for FIRDAPSE and AGAMREE. Focus on competitive compensation, benefits, and a diverse, inclusive work environment.
• Healthcare Providers: Increased flexibility in FIRDAPSE dosing. Education on LEMS diagnosis and treatment, including SCLC-related LEMS. Access to AGAMREE for DMD.
• Third-Party Payors: Continued engagement on coverage and reimbursement for FIRDAPSE and AGAMREE. Subject to increasing pressure from government and private payors on drug pricing and rebates.
• Suppliers/Manufacturers: Continued reliance on third-party contract manufacturers for all products, with plans to transition AGAMREE manufacturing to the U.S. by end of 2026.

Next Steps

• Continue to commercialize FIRDAPSE for LEMS and improve disease awareness, including to physicians treating LEMS patients who also have small-cell lung cancer.
• Evaluate FIRDAPSE in the future for the treatment of other diseases.
• Continue to commercialize AGAMREE for DMD and seek to develop additional indications for the product.
• Conduct a Phase 1 study in healthy adults comparing vamorolone, prednisone, and deflazacort, and studying the immunosuppressive effect of multiple ascending doses of AGAMREE, with results expected by the end of Q2 2026.
• Conduct the SUMMIT registry study for AGAMREE to obtain real-world data on long-term patient safety and quality of life.
• Validate a U.S. manufacturing site for AGAMREE, expected to be completed by the end of 2026.
• Seek to acquire additional high-value, orphan-designated, synergistic drug products or companies, focusing on immediate or near-term accretive opportunities.
• Continue to defend FIRDAPSE patents in ongoing litigation against Hetero USA, Inc., with trial scheduled for March 23, 2026.
• Execute the new $200 million share repurchase program through December 31, 2026.
• Monitor and adapt to changes in healthcare policies and regulations, including those related to drug pricing (IRA, MFN models).
• Continue to expand digital and social media activities for product introduction and patient/HCP education.
• Maintain and enhance Catalyst Pathways personalized treatment support and financial assistance programs for FIRDAPSE and AGAMREE.

Key Dates

Recommendation

Catalyst Pharmaceuticals demonstrates strong financial health with significant revenue and net income growth, driven by the successful launch of AGAMREE and sustained performance of FIRDAPSE. The company's strategic focus on rare diseases, coupled with a robust cash position and a new share repurchase program, indicates a commitment to shareholder value. While FYCOMPA faces generic competition and FIRDAPSE has ongoing litigation, the favorable settlements for FIRDAPSE patents and the reduced royalty rates for FIRDAPSE U.S. sales mitigate some risks. The expansion of AGAMREE's market internationally and its potential for additional indications provide a positive long-term growth outlook. The company's ability to generate substantial cash flow and its disciplined approach to business development make it an attractive investment despite inherent industry risks.

Keywords

Biopharmaceutical, Rare Disease, Orphan Drug, LEMS, DMD, Epilepsy, FIRDAPSE, AGAMREE, FYCOMPA, SEC Filing, 10-K, Patent Litigation, Drug Development, Commercialization, Share Repurchase, Financial Performance, Regulatory Approval, Healthcare Industry, Pharmaceuticals